

ASX Announcement

Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2


Highlights:

- RECCE® 327, a synthetic anti-infective 99.9% efficacious in confirmatory *in-vitro* screening assay against SARS-CoV-2 virus
- SARS-CoV-2 virus no-longer detectable by virus titration at 4,000ppm – minimal toxicity to Vero cells
- No toxicity identifiable at 1,333ppm or less
- U.S. *in-vivo* studies in parallel expanded to include new UK & South African COVID strains

Sydney Australia, 12 February 2021: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing New Classes of Synthetic Anti-Infectives, today announced results of RECCE® 327 (R327) demonstrating encouraging virucidal activity against the SARS-CoV-2 virus with a positive safety profile.

The finding is based on independent tests conducted by the CSIRO/ Doherty Institute as part of its SARS-CoV-2 Anti-viral Screening Program.

RECCE® 327 RT-PCR and Cell viability data



ASX: RCE

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 T +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

R327 showed a reduction in SARS-CoV-2 viral genome numbers **at 4,000ppm and virus was no longer detectable by viral titration**; the RT-PCR detected the 3-log drop in viral genome copies (99.9% reduction). PCR is a highly sensitive technique for viral detection and quantitation – the first choice in COVID swab testing in humans and animals¹. Antiviral testing was conducted in triplicate with a very small variance bar above the 4,000ppm data point. Minimal toxicity was observed at 4,000ppm of R327; there was no cytotoxicity at or below 1,333ppm.

Further testing will be required at higher dose levels to establish the IC 50 and cytotoxicity which will then allow the Company to decide whether to pursue R327 as an anti SARS-CoV2 inhibitor candidate. Statistical significance was not relevant in this study. All intellectual property rights are retained by the Company with data to be reported as becomes available.

In parallel to the testing at CSIRO/Doherty Institute in Australia, a leading contract research organisation in the United States is expanding its *in-vivo* studies of RECCE compounds against SARS-CoV-2 in ferrets to include emerging UK and South African variant strains of the virus. These studies continue to progress well with results on-track within the present quarter.

Whilst Recce is delighted by the results, further testing must be completed before R327 is confirmed as being active against the SARS-CoV-2 virus.

Non-Executive Chairman Dr. John Prendergast said, “We continue to be encouraged by the results from the antiviral SARS-CoV-2 screening program as it reinforces our belief in the potential of R327 against COVID-19 including emerging variant strains. We would like to thank the Doherty Institute for performing the experiments and look forward to coming studies”

This announcement has been approved for release by Recce Pharmaceuticals Board.

¹ <https://pubmed.ncbi.nlm.nih.gov/21819328/>



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327, RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065